NovaBridge Biosciences (NBP) Change in Cash (2019 - 2025)

NovaBridge Biosciences (NBP) posted quarterly Change in Cash of -$17.4 million for Q4 2025, down 57.56% year-on-year from -$41.1 million in Q4 2024, and down 127.82% on a QoQ basis from $62.7 million in Q3 2025.

NovaBridge Biosciences (NBP) Change in Cash (2019 - 2025) Analysis & Trends

NovaBridge Biosciences (NBP) has reported Change in Cash for 4 consecutive years, with -$17.4 million the latest figure, recorded in Q4 2025.

  • Quarterly Change in Cash fell 57.56% year-over-year to -$17.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$38.5 million (down 109.86% YoY) and the FY2025 annual result came in at $142.4 million, up 158.73% from the prior year.
  • Change in Cash eased to -$17.4 million in Q4 2025 per NBP's latest filing, from $62.7 million in the prior quarter.
  • Over the last five years, Change in Cash for NBP reached as high as $62.7 million in Q3 2025 and fell as low as -$72.6 million in Q3 2024.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Cash (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -22.03 Mn
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 243.78 Mn
4 NuCana 279.75 Bn 279.75 Bn - -1.34 Mn
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 417.10 Mn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -153.10 Mn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - 57.19 Mn
10 NovaBridge Biosciences 389.86 Mn 389.86 Mn - -17.43 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 -17.43 Mn
Sep 30, 2025 62.66 Mn
Dec 31, 2024 -11.06 Mn
Sep 30, 2024 -72.63 Mn
Dec 31, 2020 271.42 Mn
Sep 30, 2020 202.27 Mn
Dec 31, 2019 -12.45 Mn